S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

$46.69
-0.13 (-0.28%)
(As of 03/28/2024 ET)
Today's Range
$46.28
$47.12
50-Day Range
$43.02
$53.69
52-Week Range
$31.52
$54.98
Volume
543,698 shs
Average Volume
764,031 shs
Market Capitalization
$3.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$91.55

Ultragenyx Pharmaceutical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
96.1% Upside
$91.55 Price Target
Short Interest
Healthy
4.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.62mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.64 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.34) to ($5.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.60 out of 5 stars

Medical Sector

112th out of 938 stocks

Biotechnology Industry

4th out of 28 stocks

RARE stock logo

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RARE Stock Price History

RARE Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Ultragenyx Pharmaceutical Inc.
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
RARE Apr 2024 50.000 put
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Ultragenyx to Participate at Investor Conferences in March
Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RARE
Employees
1,276
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$91.55
High Stock Price Target
$133.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+96.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-606,640,000.00
Net Margins
-139.70%
Pretax Margin
-140.12%

Debt

Sales & Book Value

Annual Sales
$434.25 million
Book Value
$3.35 per share

Miscellaneous

Free Float
76,704,000
Market Cap
$3.84 billion
Optionable
Optionable
Beta
0.66

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives


RARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price target for 2024?

10 brokers have issued 1 year price targets for Ultragenyx Pharmaceutical's shares. Their RARE share price targets range from $48.00 to $133.00. On average, they anticipate the company's stock price to reach $91.55 in the next twelve months. This suggests a possible upside of 96.1% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2024?

Ultragenyx Pharmaceutical's stock was trading at $47.82 at the beginning of the year. Since then, RARE stock has decreased by 2.4% and is now trading at $46.69.
View the best growth stocks for 2024 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.13. The biopharmaceutical company earned $127.39 million during the quarter, compared to analysts' expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative trailing twelve-month return on equity of 369.54%. The firm's revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter last year, the business posted ($2.16) EPS.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $504.3 million.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.56%), Vanguard Group Inc. (10.53%), RTW Investments LP (8.39%), Wellington Management Group LLP (5.36%), Sands Capital Management LLC (5.02%) and Price T Rowe Associates Inc. MD (4.20%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg.
View institutional ownership trends
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RARE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners